<PAGE>


------------------------------------------------------------------------------





                   COMMON STOCK AND WARRANT PURCHASE AGREEMENT

                                  by and among

                       NexMed, Inc., as Issuer and Seller

                                       and

                   the Purchasers named herein, as Purchasers











                                  June 18, 2004



------------------------------------------------------------------------------

<PAGE>

<TABLE>
<CAPTION>

                         Table of Exhibits and Schedules
                         -------------------------------

   <S>                  <C>
Exhibit A         Form of Warrant

Exhibit B         Form of Investor Rights Agreement

Exhibit C         Form of Opinion of Seller's Counsel

Exhibit D         Form of Opinion of Nevada Counsel

Exhibit E         Form of Closing Escrow Agreement

Schedule 1                 Purchasers and Shares of Common Stock and Warrants Purchased

Schedule 3.10              Litigation

Schedule 3.11              Absence of Certain Changes

Schedule 3.15              Intellectual Property

Schedule 3.17              Preemptive Rights

Schedule 3.19              Subsidiaries and Investments

Schedule 3.20              Capitalization

Schedule 3.21              Options, Warrants, Rights

Schedule 3.22              Employees, Employment Agreements and Employee Benefit Plans

Schedule 3.27              Brokers

</TABLE>

<PAGE>


         COMMON STOCK AND WARRANT PURCHASE AGREEMENT (the "Agreement") dated as
of June 18, 2004, by and among NexMed, Inc., a Nevada corporation (the
"Seller"), and each of the persons listed on Schedule 1 hereto (each is
individually referred to as a "Purchaser" and collectively, the "Purchasers").

                                 W I T N E S S:

         WHEREAS, each of the Purchasers is willing to purchase from the Seller,
and the Seller desires to sell to the Purchasers, shares of the Seller's common
stock, $0.001 par value (the "Common Stock"), and Common Stock Purchase Warrants
(the "Warrants") entitling the holders thereof to purchase additional shares of
Common Stock, for an aggregate purchase price up to $8.75 million, as more fully
set forth herein.

         NOW THEREFORE, in consideration of the mutual promises and
representations, warranties, covenants and agreements set forth herein, the
parties hereto, intending to be legally bound, hereby agree as follows:

                          ARTICLE I - PURCHASE AND SALE

         1.1      Purchase and Sale.

         (a) On the terms and subject to the conditions set forth in this
Agreement, at the Closing (as defined in Section 2.2), the Seller will sell and
each of the Purchasers will purchase the number of shares of Common Stock set
forth on Schedule 1 hereto at a price per share equal to $1.50. In addition,
each Purchaser shall receive at the Closing Warrants to purchase the number of
shares of Common Stock equal to 35% of the number of Shares purchased by such
Purchaser at Closing hereunder as set forth on Schedule 1 hereto.

         (b) The shares of Common Stock to be issued upon Closing hereunder are
referred to herein as the "Shares," and the shares of Common Stock issuable upon
exercise of the Warrants are referred to herein as the "Warrant Shares."

         1.2 Terms of the Warrants. The terms and provisions of the Warrants are
more fully set forth in the form of Common Stock Purchase Warrant, attached
hereto as Exhibit A.

         1.3      Transfers; Legends.

         (a) Except as required by federal securities laws and the securities
law of any state or other jurisdiction within the United States, the Shares,
Warrants and Warrant Shares (collectively, the "Securities") may be transferred,
in whole or in part, by any of the Purchasers at any time. Any such transfer
shall be made by a Purchaser in accordance with applicable law. In connection
with any transfer of Securities other than pursuant to an effective registration
statement under the Securities Act of 1933, as amended (the "Securities Act"),
or to the Seller, the Seller may require the transferor thereof to furnish to
the Seller an opinion of counsel selected by the transferor, such counsel and
the form and substance of which opinion shall be reasonably satisfactory to the
Seller and Seller's counsel, to the effect that such transfer does not require
registration under the Securities Act; provided, that in the case of a transfer
pursuant to

                                       1
<PAGE>

Rule 144 under the Securities Act, no opinion shall be required if
the transferor provides the Seller with a customary seller's representation
letter, and if such sale is not pursuant to subsection (k) of Rule 144, a
customary broker's representation letter and Form 144. Notwithstanding the
foregoing, the Seller hereby consents to and agrees to register on the books of
the Seller and with any transfer agent for the securities of the Seller, without
any such legal opinion, any transfer of Securities by a Purchaser to an
Affiliate of such Purchaser, provided that the transferee certifies to the
Seller that it is an Affiliate of such Purchaser and an "accredited investor" as
defined in Rule 501(a) under the Securities Act and that it is acquiring the
Securities solely for investment purposes (subject to the qualifications hereof)
and not with a view to, or for, resale, distribution or fractionalization
thereof in whole or in part in violation of the Securities Act. Any transferee
shall agree to be bound by the terms of the Investor Rights Agreement and this
Agreement. The Seller shall reissue certificates evidencing the Securities upon
surrender of certificates evidencing the Securities being transferred in
accordance with this Section 1.3(a). In connection with any transfer of Warrants
after the Registration Statement (as defined in the Investor Rights Agreement)
is declared effective under the Securities Act, the transferor of such Warrants
shall reimburse the Seller for its reasonable out of pocket costs in connection
with such transfer (including without limitation the reasonable attorneys fees
for preparing and filing a prospectus supplement with the SEC and/or delivering
an updated opinion letter to the Seller's transfer agent). An "Affiliate" means
any Person (as such term is defined below) that, directly or indirectly through
one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 144
under the Securities Act. With respect to a Purchaser, any investment fund or
managed account that is managed on a discretionary basis by the same investment
manager as such Purchaser will be deemed to be an Affiliate of such Purchaser. A
"Person" means any individual or corporation, partnership, trust, incorporated
or unincorporated association, joint venture, limited liability company, joint
stock company, government (or an agency or subdivision of any thereof) or other
entity of any kind.

         (b) The certificates representing the Shares, unless such Shares are
eligible for resale without registration pursuant to Rule 144(k) under the
Exchange Act, shall bear the following legend:

"THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT UNLESS, IN THE
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE SELLER, SUCH REGISTRATION IS
NOT REQUIRED."

"THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS
CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN INVESTOR RIGHTS
AGREEMENT DATED AS OF JUNE 18, 2004, AS AMENDED FROM TIME TO TIME, AMONG THE
COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH
AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF
RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY."

                                       2
<PAGE>

                     ARTICLE II - PURCHASE PRICE AND CLOSING

         2.1 Purchase Price. The aggregate purchase price (the "Purchase Price")
to be paid by the Purchasers to the Seller to acquire the Shares and the
applicable Warrants shall be the total amounts set forth on Schedule 1 hereto.

         2.2 The Closing. The closing of the transactions contemplated under
this Agreement (the "Closing") will take place as promptly as practicable, but
no later than five (5) business days following satisfaction or waiver of the
conditions set forth in Article 6.1(a) and 6.2(a) (other than those conditions
which by their terms are not to be satisfied or waived until the Closing), at
the offices of Wiggin and Dana LLP, 400 Atlantic Street, Stamford, Connecticut
06901. The date on which the Closing occurs is the "Closing Date."

           ARTICLE III - REPRESENTATIONS AND WARRANTIES OF THE SELLER

         The Seller represents and warrants to the Purchasers as follows:

         3.1 Corporate Existence and Power; Subsidiaries. The Seller and its
Subsidiaries are corporations duly incorporated, validly existing and in good
standing under the laws of the state in which they are incorporated, and have
all corporate powers required to carry on their business as now conducted. The
Seller and its Subsidiaries are duly qualified to do business as a foreign
corporation and are in good standing in each jurisdiction where the character of
the property owned or leased by them or the nature of their activities makes
such qualification necessary, except for those jurisdictions where the failure
to be so qualified would not have a Material Adverse Effect on the Seller or any
of its Subsidiaries. For purposes of this Agreement, the term "Material Adverse
Effect" means, with respect to any person or entity, a material adverse effect
on its and its Subsidiaries' condition (financial or otherwise), business,
properties, assets, liabilities (including contingent liabilities), results of
operations or current prospects, taken as a whole. True and complete copies of
the Seller's Articles of Incorporation, as amended, and Bylaws, as amended, as
currently in effect and as will be in effect on the Closing Date (collectively,
the "Articles and Bylaws"), have previously been provided to the Purchasers. For
purposes of this Agreement, the term "Subsidiary" or "Subsidiaries" means, with
respect to any entity, any corporation or other organization of which securities
or other ownership interests having ordinary voting power to elect a majority of
the board of directors or other persons performing similar functions are
directly or indirectly owned by such entity or of which such entity is a partner
or is, directly or indirectly, the beneficial owner of 50% or more of any class
of equity securities or equivalent profit participation interests. The Seller
has no Subsidiaries other than the following, each of which, unless otherwise
indicated, is wholly-owned by the Seller:

                  (a)   NexMed Holdings, Inc., a Delaware corporation,

                  (b)   NexMed (U.S.A.), Inc., a Delaware corporation,

                  (c)   NexMed International Limited, organized under British
                        Virgin Islands law,

                                       3
<PAGE>

                         (1)   NexMed (Americas) Limited, organized under Nova
                               Scotia law and a wholly-owned subsidiary of
                               NexMed International Limited, and

                         (2)   NexMed International (Hong Kong) Ltd. organized
                               under Hong Kong law and a wholly-owned subsidiary
                               of NexMed International Limited.

         3.2 Corporate Authorization. The execution, delivery and performance by
the Seller of this Agreement, the Warrants, the Investor Rights Agreement, the
Closing Escrow Agreement (as defined below), and each of the other documents
executed pursuant to and in connection with this Agreement (collectively, the
"Related Documents"), and the consummation of the transactions contemplated
hereby and thereby (including, but not limited to, the sale and delivery of the
Shares and the Warrants, and the subsequent issuance of the Warrant Shares upon
exercise of the Warrants) have been duly authorized, and no additional corporate
or stockholder action is required for the approval of this Agreement. The
Warrant Shares have been duly reserved for issuance by the Seller. This
Agreement and the Related Documents have been or, to the extent contemplated
hereby or by the Related Documents, will be duly executed and delivered and
constitute the legal, valid and binding agreement of the Seller, enforceable
against the Seller in accordance with their terms, except as may be limited by
bankruptcy, reorganization, insolvency, moratorium and similar laws of general
application relating to or affecting the enforcement of rights of creditors, and
except as enforceability of its obligations hereunder are subject to general
principles of equity (regardless of whether such enforceability is considered in
a proceeding in equity or at law).

         3.3 Charter, Bylaws and Corporate Records. The minute books of the
Seller and its Subsidiaries contain complete and accurate records of all
meetings and other corporate actions of the board of directors, committees of
the board of directors, incorporators and stockholders of the Seller and its
Subsidiaries from September 15, 1995 to the date hereof. All material corporate
decisions and actions have been validly made or taken. All corporate books,
including without limitation the share transfer register, comply with applicable
laws and regulations and have been regularly updated. Such books fully and
correctly reflect all the decisions of the stockholders.


         3.4 Governmental Authorization. Except as otherwise specifically
contemplated in this Agreement and the Related Documents, and except for: (i)
the filings referenced in Section 5.10; (ii) the filing of a Form D with respect
to the Shares and Warrants under Regulation D under the Securities Act; (iii)
the filing of the Registration Statement with the Commission; (iv) the
application(s) to each trading market for the listing of the Shares and the
Warrant Shares for trading thereon; and (v) any filings required under state
securities laws that are permitted to be made after the date hereof, the
execution, delivery and performance by the Seller of this Agreement and the
Related Documents, and the consummation of the transactions contemplated hereby
and thereby (including, but not limited to, the sale and delivery of the Shares
and Warrants and the subsequent issuance of the Warrant Shares upon exercise of
the Warrants, as applicable) by the Seller require no action by or in respect
of, or filing with, any governmental body, agency, official or authority.

                                       4
<PAGE>

         3.5 Non-Contravention. The execution, delivery and performance by the
Seller of this Agreement and the Related Documents, and the consummation by the
Seller of the transactions contemplated hereby and thereby (including the
issuance of the Shares and Warrant Shares) do not and will not (a) contravene or
conflict with the Articles and Bylaws of the Seller and its Subsidiaries or any
material agreement to which the Seller is a party or by which it is bound; (b)
contravene or conflict with or constitute a violation of any provision of any
law, regulation, judgment, injunction, order or decree binding upon or
applicable to the Seller or its Subsidiaries; (c) constitute a default (or would
constitute a default with notice or lapse of time or both) under or give rise to
a right of termination, cancellation or acceleration or loss of any benefit
under any material agreement, contract or other instrument binding upon the
Seller or its Subsidiaries or under any material license, franchise, permit or
other similar authorization held by the Seller or its Subsidiaries; or (d)
result in the creation or imposition of any Lien (as defined below) on any asset
of the Seller or its Subsidiaries. For purposes of this Agreement, the term
"Lien" means, with respect to any asset, any mortgage, lien, pledge, charge,
security interest, claim or encumbrance of any kind in respect of such asset.

         3.6 SEC Documents. The Seller is obligated under the Securities
Exchange Act of 1934, as amended (the "Exchange Act") to file reports pursuant
to Sections 13 or 15(d) thereof (all such reports filed or required to be filed
by the Seller, including all exhibits thereto or incorporated therein by
reference, and all documents filed by the Seller under the Securities Act
hereinafter called the "SEC Documents"). The Seller has filed all reports or
other documents required to be filed under the Exchange Act. All SEC Documents
filed by the Seller as of or for any period beginning on or after January 1,
2002, (i) were prepared in all material respects in accordance with the
requirements of the Exchange Act and (ii) did not at the time they were filed
(or, if amended or superseded by a filing prior to the date hereof, then on the
date of such filing) contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were
made, not misleading. The Seller has previously delivered to the Purchaser a
correct and complete copy of each report (including, without limitation, the
2004 Proxy Statement) which the Seller filed with the Securities and Exchange
Commission (the "SEC" or the "Commission") under the Exchange Act for any period
ending on or after December 31, 2003 (the "Recent Reports"). None of the
information about the Seller or any of its Subsidiaries which has been disclosed
to the Purchasers herein or in the course of discussions and negotiations with
respect hereto which is not disclosed in the Recent Reports is or was required
to be so disclosed, and no material non-public information has been disclosed to
the Purchasers.

         3.7 Financial Statements. Each of the Seller's audited consolidated
balance sheet and related consolidated statements of income, cash flows and
changes in stockholders' equity (including the related notes) as of and for the
years ended December 31, 2003 and December 31, 2002, as contained in the Recent
Reports (collectively, the "Seller's Financial Statements" or the "Financial
Statements") (x) present fairly in all material respects the financial position
of the Seller and its Subsidiaries on a consolidated basis as of the dates
thereof and the results of operations, cash flows and stockholders' equity as of
and for each of the periods then ended, and (y) were prepared in accordance with
generally accepted accounting principals ("GAAP")

                                       5
<PAGE>

applied on a consistent basis throughout the periods involved, in each case,
except as otherwise indicated in the notes thereto.

         3.8 Compliance with Law. The Seller and its Subsidiaries are in
compliance and have conducted their business so as to comply with all laws,
rules and regulations, judgments, decrees or orders of any court, administrative
agency, commission, regulatory authority or other governmental authority or
instrumentality, domestic or foreign, applicable to their operations, the
violation of which would cause a Material Adverse Affect. There are no judgments
or orders, injunctions, decrees, stipulations or awards (whether rendered by a
court or administrative agency or by arbitration), including any such actions
relating to affirmative action claims or claims of discrimination, against the
Seller or its Subsidiaries or against any of their properties or businesses.

         3.9 No Defaults. The Seller and its Subsidiaries are not, nor have they
received notice that they would be with the passage of time, giving of notice,
or both, (i) in violation of any provision of their Articles and Bylaws (ii) in
default or violation of any term, condition or provision of (A) any judgment,
decree, order, injunction or stipulation applicable to the Seller or its
Subsidiaries or (B) any material agreement, note, mortgage, indenture, contract,
lease or instrument, permit, concession, franchise or license to which the
Seller or its Subsidiaries are a party or by which the Seller or its
Subsidiaries or their properties or assets may be bound, and no circumstances
exist which would entitle any party to any material agreement, note, mortgage,
indenture, contract, lease or instrument to which such Seller or its
Subsidiaries are a party, to terminate such as a result of such Seller or its
Subsidiaries, having failed to meet any material provision thereof including,
but not limited to, meeting any applicable milestone under any material
agreement or contract.

         3.10 Litigation. Except as disclosed in the Recent Reports or on
Schedule 3.10, there is no action, suit, proceeding, judgment, claim or
investigation pending or, to the best knowledge of the Seller, threatened
against the Seller and its Subsidiaries which could, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect on the
Seller or its Subsidiaries or which in any manner challenges or seeks to
prevent, enjoin, alter or materially delay any of the transactions contemplated
hereby, and there is no basis for the assertion of any of the foregoing.

         There are no claims or complaints existing or, to the knowledge of the
Seller or its Subsidiaries, threatened for product liability in respect of any
product of the Seller or its Subsidiaries, and the Seller and its Subsidiaries
are not aware of any basis for the assertion of any such claim.

         3.11 Absence of Certain Changes. Since December 31, 2003, the Seller
has conducted its business only in the ordinary course and there has not
occurred, except as set forth in the Recent Reports or any exhibit thereto or
incorporated by reference therein:

         (a) Any event that could reasonably be expected to have a Material
Adverse Effect on the Seller or any of its Subsidiaries;

                                       6
<PAGE>

         (b) Any amendments or changes in the Articles or Bylaws of the Seller
and its Subsidiaries;

         (c) Any damage, destruction or loss, whether or not covered by
insurance, that would, individually or in the aggregate, have or would be
reasonably likely to have, a Material Adverse Effect on the Seller and its
Subsidiaries;

         (d) Except as set forth on Schedule 3.11(d), any

                  (i) incurrence, assumption or guarantee by the Seller or its
         Subsidiaries of any debt for borrowed money other than for equipment
         leases;

                  (ii) issuance or sale of any securities convertible into or
         exchangeable for securities of the Seller other than to directors,
         employees and consultants pursuant to existing equity compensation or
         stock purchase plans of the Seller;

                  (iii) issuance or sale of options or other rights to acquire
         from the Seller or its Subsidiaries, directly or indirectly, securities
         of the Seller or any securities convertible into or exchangeable for
         any such securities, other than options issued to directors, employees
         and consultants in the ordinary course of business in accordance with
         past practice;

                  (iv) issuance or sale of any stock, bond or other corporate
         security;

                  (v) discharge or satisfaction of any material Lien, other than
         current liabilities incurred since December 31, 2003 in the ordinary
         course of business;

                  (vi) declaration or making any payment or distribution to
         stockholders or purchase or redemption of any share of its capital
         stock or other security;

                  (vii) sale, assignment or transfer any of its intangible
         assets except in the ordinary course of business, or cancellation of
         any debt or claim except in the ordinary course of business;

                  (viii) waiver of any right of substantial value whether or not
         in the ordinary course of business;

                  (ix) material change in officer compensation except in the
         ordinary course of business and consistent with past practices; or

                  (x) other commitment (contingent or otherwise) to do any of
         the foregoing.

         (e) Any creation, sufferance or assumption by the Seller or any of its
Subsidiaries of any Lien on any asset (other than Liens existing on the date
hereof or in connection with equipment leases and working capital lines of
credit set forth on Schedule 3.11(e)) or any making of any loan, advance or
capital contribution to or investment in any Person in an aggregate amount which
exceeds $25,000 outstanding at any time;

                                       7

<PAGE>

        (f) Any entry into, amendment of, relinquishment, termination or
non-renewal by the Seller or its Subsidiaries of any material contract, license,
lease, transaction, commitment or other right or obligation, other than in the
ordinary course of business; or

         (g) Any transfer or grant of a right with respect to the trademarks,
trade names, service marks, trade secrets, copyrights or other intellectual
property rights owned or licensed by the Seller or its Subsidiaries, except as
among the Seller and its Subsidiaries.

         3.12 No Undisclosed Liabilities. Except as set forth in the Recent
Reports, and except for liabilities and obligations incurred in the ordinary
course of business since December 31, 2003, as of the date hereof, (i) the
Seller and its Subsidiaries do not have any material liabilities or obligations
(absolute, accrued, contingent or otherwise) which, and (ii) there has not been
any aspect of the prior or current conduct of the business of the Seller or its
Subsidiaries which may form the basis for any material claim by any third party
which if asserted could result in any such material liabilities or obligations
which, are not fully reflected, reserved against or disclosed in the balance
sheet of the Seller as at December 31, 2003.

         3.13 Taxes. All tax returns and tax reports required to be filed with
respect to the income, operations, business or assets of the Seller and its
Subsidiaries have been timely filed (or appropriate extensions have been
obtained) with the appropriate governmental agencies in all jurisdictions in
which such returns and reports are required to be filed, and all of the
foregoing as filed are correct and complete and, in all material respects,
reflect accurately all liability for taxes of the Seller and its Subsidiaries
for the periods to which such returns relate, and all amounts shown as owing
thereon have been paid. All income, profits, franchise, sales, use, value added,
occupancy, property, excise, payroll, withholding, FICA, FUTA and other taxes
(including interest and penalties), if any, collectible or payable by the Seller
and its Subsidiaries or relating to or chargeable against any of its material
assets, revenues or income or relating to any employee, independent contractor,
creditor, stockholder or other third party through the Closing Date, were fully
collected and paid by such date if due by such date or provided for by adequate
reserves in the Financial Statements as of and for the periods ended December
31, 2003 (other than taxes accruing after such date) and all similar items due
through the Closing Date will have been fully paid by that date or provided for
by adequate reserves, whether or not any such taxes were reported or reflected
in any tax returns or filings. No taxation authority has sought to audit the
records of the Seller or any of its Subsidiaries for the purpose of verifying or
disputing any tax returns, reports or related information and disclosures
provided to such taxation authority, or for the Seller's or any of its
Subsidiaries' alleged failure to provide any such tax returns, reports or
related information and disclosure. No material claims or deficiencies have been
asserted against or inquiries raised with the Seller or any of its Subsidiaries
with respect to any taxes or other governmental charges or levies which have not
been paid or otherwise satisfied, including claims that, or inquiries whether,
the Seller or any of its Subsidiaries has not filed a tax return that it was
required to file, and, to the best of the Seller's knowledge, there exists no
reasonable basis for the making of any such claims or inquiries. Neither the
Seller nor any of its Subsidiaries has waived any restrictions on assessment or
collection of taxes or consented to the extension of any statute of limitations
relating to taxation.

         3.14 Interests of Officers, Directors and Other Affiliates. The
description of any

                                       8
<PAGE>

interest held, directly or indirectly, by any officer, director or other
Affiliate of Seller (other than the interests of the Seller and its Subsidiaries
in such assets) in any property, real or personal, tangible or intangible, used
in or pertaining to Seller's business, including any interest in the
Intellectual Property (as defined in Section 3.15 hereof), as set forth in the
Recent Reports, is true and complete, and no officer, director or other
Affiliate of the Seller has any interest in any property, real or personal,
tangible or intangible, used in or pertaining to the Seller's business,
including the Seller's Intellectual Property, other than as set forth in the
Recent Reports.

         3.15 Intellectual Property. Other than as set forth in the Recent
Reports:

         (a) the Seller or a Subsidiary thereof has the right to use or is the
sole and exclusive owner of all right, title and interest in and to all foreign
and domestic patents, patent rights, trademarks, service marks, trade names,
brands and copyrights (whether or not registered and, if applicable, including
pending applications for registration) owned, used or controlled by the Seller
and its Subsidiaries (collectively, the "Rights") and in and to each material
invention, software, trade secret, technology, product, composition, formula,
method of process used by the Seller or its Subsidiaries (the Rights and such
other items, the "Intellectual Property"), and, to the Seller's knowledge, has
the right to use the same, free and clear of any claim or conflict with the
rights of others;

         (b) no royalties or fees (license or otherwise) are payable by the
Seller or its  Subsidiaries to any Person by reason of the ownership or use of
any of the Intellectual Property except as set forth on Schedule 3.15;

         (c) there have been no claims made against the Seller or its
Subsidiaries asserting the invalidity, abuse, misuse, or unenforceability of any
of the Intellectual Property, and, to its knowledge, there are no reasonable
grounds for any such claims;

         (d) neither the Seller nor its Subsidiaries have made any claim of any
violation or infringement by others of its rights in the Intellectual Property,
and to the best of the Seller's knowledge, no reasonable grounds for such claims
exist; and

         (e) neither the Seller nor its Subsidiaries have received notice that
it is in conflict with or infringing upon the asserted rights of others in
connection with the Intellectual Property.

         3.16 Restrictions on Business Activities. Other than as set forth in
the Recent Reports, there is no agreement, judgment, injunction, order or decree
binding upon the Seller or its Subsidiaries which has or could reasonably be
expected to have the effect of prohibiting or materially impairing any business
practice of the Seller or its Subsidiaries, any acquisition of property by the
Seller or its Subsidiaries or the conduct of business by the Seller or its
Subsidiaries as currently conducted or as currently proposed to be conducted by
the Seller.

         3.17 Preemptive Rights. Except as set forth in Schedule 3.17, none of
the stockholders of the Seller possess any preemptive rights in respect of the
Shares or Warrant Shares to be issued to the Purchasers upon exercise of the
Warrants, as applicable.

         3.18 Insurance. The insurance policies providing insurance coverage to
the Seller or its

                                       9
<PAGE>

Subsidiaries including for product liability are adequate for the business
conducted by the Seller and its Subsidiaries (currently limited to the
testing phase) and are sufficient for compliance by the Seller and its
Subsidiaries with all requirements of law and all material agreements to which
the Seller or its Subsidiaries are a party or by which any of their assets are
bound. All of such policies are in full force and effect and are valid and
enforceable in accordance with their terms, and the Seller and its Subsidiaries
have complied with all material terms and conditions of such policies, including
premium payments. None of the insurance carriers has indicated to the Seller or
its Subsidiaries an intention to cancel any such policy.

         3.19 Subsidiaries and Investments. Except as set forth in the Recent
Reports or on Schedule 3.19, the Seller has no Subsidiaries or Investments. For
purposes of this Agreement, the term "Investments" shall mean, with respect to
any Person, all advances, loans or extensions of credit to any other Person, all
purchases or commitments to purchase any stock, bonds, notes, debentures or
other securities of any other Person, and any other investment in any other
Person, including partnerships or joint ventures (whether by capital
contribution or otherwise) or other similar arrangement (whether written or
oral) with any Person, including but not limited to arrangements in which (i)
the Person shares profits and losses, (ii) any such other Person has the right
to obligate or bind the Person to any third party, or (iii) the Person may be
wholly or partially liable for the debts or obligations of such partnership,
joint venture or other arrangement.

         3.20 Capitalization. The authorized capital stock of the Seller
consists of 80,000,000 shares of common stock, $0.001 par value per share, of
which 40,342,513 shares are issued and outstanding as of the date hereof, and
10,000,000 shares of preferred stock, issuable in one or more classes or series,
with such relative rights and preferences as the Board of Directors may
determine, none of which has been authorized for issuance other than 1,000,000
shares of Series A Junior Participating Preferred Stock, $0.001 par value per
share, none of which, immediately prior to the Closing, has been issued or is
outstanding, and other than the 800 shares of the Seller's Series B 8%
Cumulative Convertible Preferred Stock, 800 of which have been issued and none
of which, immediately prior to the Closing, are outstanding. All shares of the
Seller's issued and outstanding capital stock have been duly authorized, are
validly issued and outstanding, and are fully paid and nonassessable. No
securities issued by the Seller from the date of its incorporation to the date
hereof were issued in violation of any statutory or common law preemptive
rights. There are no dividends which have accrued or been declared but are
unpaid on the capital stock of the Seller. All taxes required to be paid by
Seller in connection with the issuance and any transfers of the Seller's capital
stock have been paid. Except as set forth on Schedule 3.20, all permits or
authorizations required to be obtained from or registrations required to be
effected with any Person in connection with any and all issuances of securities
of the Seller from the date of the Seller's incorporation to the date hereof
have been obtained or effected, and all securities of the Seller have been
issued and are held in accordance with the provisions of all applicable
securities or other laws.

         3.21 Options, Warrants, Rights. Except as set forth on Schedule 3.21,
there are no outstanding (a) securities, notes or instruments convertible into
or exercisable for any of the capital stock or other equity interests of the
Seller or its Subsidiaries; (b) options, warrants, subscriptions or other rights
to acquire capital stock or other equity interests of the Seller or its

                                       10
<PAGE>

Subsidiaries; or (c) commitments, agreements or understandings of any kind,
including employee benefit arrangements, relating to the issuance or repurchase
by the Seller or its Subsidiaries of any capital stock or other equity interests
of the Seller or its Subsidiaries, any such securities or instruments
convertible or exercisable for securities or any such options, warrants or
rights. Except as set forth on Schedule 3.21, neither the Seller nor the
Subsidiaries have granted anti-dilution rights to any person or entity in
connection with any outstanding option, warrant, subscription or any other
instrument convertible or exercisable for the securities of the Seller or any of
its Subsidiaries. Other than the rights granted to the Purchasers under the
Investor Rights Agreement, there are no outstanding rights which permit the
holder thereof to cause the Seller or the Subsidiaries to file a registration
statement under the Securities Act or which permit the holder thereof to include
securities of the Seller or any of its Subsidiaries in a registration statement
filed by the Seller or any of its Subsidiaries under the Securities Act, and
there are no outstanding agreements or other commitments which otherwise relate
to the registration of any securities of the Seller or any of its Subsidiaries
for sale or distribution in any jurisdiction, except as set forth on Schedule
3.21.

         3.22 Employees, Employment Agreements and Employee Benefit Plans.
Except as set forth in the Recent Reports or on Schedule 3.22, there are no
employment, consulting, severance or indemnification arrangements, agreements,
or understandings between the Seller and any officer, director, consultant or
employee of the Seller or its Subsidiaries (the "Employment Agreements"). No
Employment Agreement provides for the acceleration or change in the award,
grant, vesting or determination of options, warrants, rights, severance
payments, or other contingent obligations of any nature whatsoever of the Seller
or its Subsidiaries in favor of any such parties in connection with the
transactions contemplated by this Agreement. Except as disclosed in the Recent
Reports or on Schedule 3.22, the terms of employment or engagement of all
directors, officers, employees, agents, consultants and professional advisors of
the Seller and its Subsidiaries are such that their employment or engagement may
be terminated upon not more than two weeks' notice given at any time without
liability for payment of compensation or damages and the Seller and its
Subsidiaries have not entered into any agreement or arrangement for the
management of their business or any part thereof other than with their directors
or employees.

         3.23 Absence of Certain Business Practices. Neither the Seller, nor any
Affiliate of the Seller, nor to the knowledge of the Seller, any agent or
employee of the Seller, any other Person acting on behalf of or associated with
the Seller, or any individual related to any of the foregoing Persons, acting
alone or together, has: (a) received, directly or indirectly, any rebates,
payments, commissions, promotional allowances or any other economic benefits,
regardless of their nature or type, from any customer, supplier, trading
company, shipping company, governmental employee or other Person with whom the
Seller has done business directly or indirectly; or (b) directly or indirectly,
given or agreed to give any gift or similar benefit to any customer, supplier,
trading company, shipping company, governmental employee or other Person who is
or may be in a position to help or hinder the business of the Seller (or assist
the Seller in connection with any actual or proposed transaction) which (i) may
subject the Seller to any damage or penalty in any civil, criminal or
governmental litigation or proceeding, (ii) if not given in the past, may have
had an adverse effect on the Seller or (iii) if not continued in the future, may
adversely affect the assets, business, operations or prospects of the Seller or
subject the Seller to

                                       11
<PAGE>

suit or penalty in any private or governmental litigation or proceeding.

         3.24 Products and Services. To the knowledge of the Seller and except
as disclosed in the Recent Reports, there exists no set of facts (i) which could
furnish a basis for the withdrawal, suspension or cancellation of any
registration, license, permit or other governmental approval or consent of any
governmental or regulatory agency with respect to any product or service
developed or provided by the Seller or its Subsidiaries, (ii) which could
furnish a basis for the withdrawal, suspension or cancellation by order of any
state, federal or foreign court of law of any product or service, or (iii) which
could have a Material Adverse Effect on the continued operation of any facility
of the Seller or its Subsidiaries or which could otherwise cause the Seller or
its Subsidiaries to withdraw, suspend or cancel any such product or service from
the market or to change the marketing classification of any such product or
service. Each product or service provided by Seller or its Subsidiaries has been
provided in accordance in all material respects with the specifications under
which such product or service normally is and has been provided and the
provisions of all applicable laws or regulations.

         3.25 Environmental Matters. None of the premises or any properties
owned, occupied or leased by the Seller or its Subsidiaries (the "Premises") has
been used by the Seller or the Subsidiaries or, to the Seller's knowledge, by
any other Person, to manufacture, treat, store, or dispose of any substance that
has been designated to be a "hazardous substance" under applicable Environmental
Laws (hereinafter defined) ("Hazardous Substances") in violation of any
applicable Environmental Laws. To its knowledge, the Seller has not disposed of,
discharged, emitted or released any Hazardous Substances which would require,
under applicable Environmental Laws, remediation, investigation or similar
response activity. No Hazardous Substances are present as a result of the
actions of the Seller or, to the Seller's knowledge, any other Person, in, on or
under the Premises which would give rise to any liability or clean-up
obligations of the Seller under applicable Environmental Laws. The Seller and,
to the Seller's knowledge, any other Person for whose conduct it may be
responsible pursuant to an agreement or by operation of law, are in compliance
with all laws, regulations and other federal, state or local governmental
requirements, and all applicable judgments, orders, writs, notices, decrees,
permits, licenses, approvals, consents or injunctions in effect on the date of
this Agreement relating to the generation, management, handling, transportation,
treatment, disposal, storage, delivery, discharge, release or emission of any
Hazardous Substance (the "Environmental Laws"). Neither the Seller nor, to the
Seller's knowledge, any other Person for whose conduct it may be responsible
pursuant to an agreement or by operation of law has received any written
complaint, notice, order, or citation of any actual, threatened or alleged
noncompliance with any of the Environmental Laws, and there is no proceeding,
suit or investigation pending or, to the Seller's knowledge, threatened against
the Seller or, to the Seller's knowledge, any such Person with respect to any
violation or alleged violation of the Environmental Laws, and, to the knowledge
of the Seller, there is no basis for the institution of any such proceeding,
suit or investigation.

         3.26 Licenses; Compliance With FDA and Other Regulatory Requirements.

         (a) General. Except as disclosed in the Recent Reports, the Seller
holds all material authorizations, consents, approvals, franchises, licenses and
permits required under applicable

                                       12
<PAGE>

law or regulation for the operation of the business of the Seller and its
Subsidiaries as presently operated (the "Governmental Authorizations"). All the
Governmental Authorizations have been duly issued or obtained and are in full
force and effect, and the Seller and its Subsidiaries are in material compliance
with the terms of all the Governmental Authorizations. The Seller and its
Subsidiaries have not engaged in any activity that, to their knowledge, would
cause revocation or suspension of any such Governmental Authorizations. The
Seller has no knowledge of any facts which could reasonably be expected to cause
the Seller to believe that the Governmental Authorizations will not be renewed
by the appropriate governmental authorities in the ordinary course. Neither the
execution, delivery nor performance of this Agreement shall adversely affect the
status of any of the Governmental Authorizations.

         (b) FDA. Without limiting the generality of the representations and
warranties made in paragraph (a) above, the Seller represents and warrants that
(i) the Seller and each of its Subsidiaries is in material compliance with all
applicable provisions of the United States Federal Food, Drug, and Cosmetic Act
(the "FDC Act"), (ii) its products and those of each of its Subsidiaries that
are in the Seller's control are not adulterated or misbranded and are in lawful
distribution, (iii) the United States Food and Drug Administration (the "FDA")
has not initiated legal action with respect to the manufacturing of the Seller's
products, such as seizures or FDA-required recalls, and Seller uses best efforts
to comply with applicable FDA good manufacturing practice regulations, (iv) all
adverse events that were known to and required to be reported by Seller to the
FDA have been reported to the FDA in a timely manner, (v) neither the Seller nor
any of its Subsidiaries is, to their knowledge, employing or utilizing the
services of any individual who has been debarred under the FDC Act, (vi) all
stability studies required to be performed for products distributed by the
Seller or any of its Subsidiaries have been completed or are ongoing in material
compliance with the applicable FDA requirements, and (vii) the Seller and its
Subsidiaries is in compliance in all material respects with all applicable
provisions of the Controlled Substances Act.

         3.27 Brokers. Except as set forth on Schedule 3.27, no broker, finder
or investment banker is entitled to any brokerage, finder's or other fee or
commission in connection with the transactions contemplated by this Agreement,
based upon any arrangement made by or on behalf of the Seller, which would make
any Purchaser liable for any fees or commissions.

         3.28 Securities Laws. Neither the Seller nor its Subsidiaries nor any
agent acting on behalf of the Seller or its Subsidiaries has taken or will take
any action which might cause this Agreement or the Warrants to violate the
Securities Act or the Exchange Act or any rules or regulations promulgated
thereunder, as in effect on the Closing Date. Assuming that all of the
representations and warranties of the Purchasers set forth in Article IV are
true, all offers and sales of capital stock, securities and notes of the Seller
were conducted and completed in compliance with the Securities Act. All shares
of capital stock and other securities issued by the Seller and its Subsidiaries
prior to the date hereof have been issued in transactions that were either
registered offerings or were exempt from the registration requirements under the
Securities Act and all applicable state securities or "blue sky" laws and in
compliance with all applicable corporate laws.

         3.29 Disclosure. No representation or warranty made by the Seller in
this Agreement,

                                       13
<PAGE>

nor in any document, written information, financial statement, certificate,
schedule or exhibit prepared and furnished by the Seller or the
representatives of the Seller pursuant hereto or in connection with the
transactions contemplated hereby, contains or will contain any untrue statement
of a material fact, or omits to state a material fact necessary to make the
statements or facts contained herein or therein not misleading in light of the
circumstances under which they were furnished.

          ARTICLE IV - REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS

         Each Purchaser, for itself only, hereby severally and not jointly,
represents and warrants to the Seller as follows:

         4.1 Existence and Power. The Purchaser is duly organized, validly
existing and in good standing under the laws of the jurisdiction of such
Purchaser's organization. The Purchaser has all powers required to carry on such
Purchaser's business as now conducted.

         4.2 Authorization. The execution, delivery and performance by the
Purchaser of this Agreement, the Related Documents to which such Purchaser is a
party, and the consummation by the Purchaser of the transactions contemplated
hereby and thereby have been duly authorized, and no additional action is
required for the approval of this Agreement or the Related Documents. This
Agreement and the Related Documents to which the Purchaser is a party have been
or, to the extent contemplated hereby, will be duly executed and delivered and
constitute valid and binding agreements of the Purchaser, enforceable against
such Purchaser in accordance with their terms, except as may be limited by
bankruptcy, reorganization, insolvency, moratorium and similar laws of general
application relating to or affecting the enforcement of rights of creditors and
except that enforceability of their obligations thereunder are subject to
general principles of equity (regardless of whether such enforceability is
considered in a proceeding in equity or at law).

         4.3 Investment. The Purchaser is acquiring the securities described
herein for its own account and not with a view to, or for sale in connection
with, any distribution thereof, nor with the intention of distributing or
reselling the same, provided, however, that by making the representation herein,
the Purchaser does not agree to hold any of the securities for any minimum or
other specific term and reserves the right to dispose of the securities at any
time in accordance with or pursuant to a registration statement or an exemption
under the Securities Act. The Purchaser is aware that none of the securities has
been registered under the Securities Act or under applicable state securities or
blue sky laws. The Purchaser is an "Accredited Investor" as such term is defined
in Rule 501 of Regulation D, as promulgated under the Securities Act.

         4.4 Reliance on Exemptions. The Purchaser understands that the Shares
and Warrants are being offered and sold to such Purchaser in reliance upon
specific exemptions from the registration requirements of United States federal
and state securities laws and that the Seller is relying upon the truth and
accuracy of, and such Purchaser's compliance with, the representations,
warranties, agreements, acknowledgments and understandings of such Purchaser set
forth herein in order to determine the availability of such exemptions and the
eligibility of such Purchaser to acquire the securities.

                                       14
<PAGE>

         4.5 Experience of the Purchaser. The Purchaser, either alone or
together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating
the merits and risks of the prospective investment in the Securities, and has so
evaluated the merits and risks of such investment. The Purchaser is able to bear
the economic risk of an investment in the securities and, at the present time,
is able to afford a complete loss of such investment.

         4.6 General Solicitation. The Purchaser is not purchasing the
Securities as a result of any advertisement, article, notice or other
communication regarding the securities published in any newspaper, magazine or
similar media or broadcast over television or radio or presented at any seminar
or any other general solicitation or general advertisement.

         4.7 Independence. The Purchaser is neither an Affiliate of any other
Purchaser nor is a member of any "group" in which any other Purchaser is a
member, except that: (a) SDS Capital Group SPC, Ltd. and BayStar Capital II, LP
are Affiliates of each other and (b) Clarion Capital Corporation, Clarion
Offshore Fund, Ltd. and Clarion Partners, L.P. are Affiliates of each other. For
purposes hereof, "group" has the meaning set forth in Section 13(d) of the
Exchange Act and applicable regulations of the Securities and Exchange
Commission.

               ARTICLE V - COVENANTS OF THE SELLER AND PURCHASERS

         5.1 Insurance. The Seller and its Subsidiaries shall, from time to time
upon the written request of the Purchasers, promptly furnish or cause to be
furnished to the Seller evidence, in form and substance reasonably satisfactory
to the Purchasers, of the maintenance of all insurance maintained by it for loss
or damage by fire and other hazards, damage or injury to persons and property,
including from product liability, and under workmen's compensation laws.

         5.2 Reporting Obligations. So long as any portion of the Warrants has
not been exercised and has not expired by its terms, the Seller shall furnish to
the Purchasers, or any other persons who hold any of the Warrants (provided that
such subsequent holders give notice to the Seller that they hold Warrants and
furnish their addresses) promptly upon their becoming available one copy of (A)
each report, notice or proxy statement sent by the Seller to its stockholders
generally, and of each regular or periodic report (pursuant to the Exchange Act)
and (B) any registration statement, prospectus or written communication pursuant
to the Securities Act relating to the issuance or registration of the Shares and
the Warrant Shares and filed by the Seller with the Commission or any securities
market or exchange on which shares of Common Stock are listed; provided,
however, that the Seller shall have no obligation to deliver periodic reports
(pursuant to the Exchange Act) under this Section 5.2 to the extent such reports
are publicly available.

         The Purchasers are hereby authorized to deliver a copy of any financial
statement or any other information relating to the business, operations or
financial condition of the Seller which may have been furnished to the
Purchasers hereunder, to any regulatory body or agency having jurisdiction over
the Purchasers or to any Person which shall, or shall have right or obligation
to

                                       15
<PAGE>

succeed to all or any part of the Purchasers' interest in the Seller or this
Agreement.

         5.3 Investigation. The representations, warranties, covenants and
agreements set forth in this Agreement shall not be affected or diminished in
any way by any investigation (or failure to investigate) at any time by or on
behalf of the party for whose benefit such representations, warranties,
covenants and agreements were made. Without limiting the generality of the
foregoing, the inability or failure of the Purchasers to discover any breach,
default or misrepresentation by the Seller under this Agreement or the Related
Documents (including under any certificate furnished pursuant to this
Agreement), notwithstanding the exercise by the Purchasers or other holders of
the Shares of their rights hereunder to conduct an investigation shall not in
any way diminish any liability hereunder.

         5.4 Further Assurances. The Seller shall, at its cost and expense, upon
written request of the Purchasers, duly execute and deliver, or cause to be duly
executed and delivered, to the Purchasers such further instruments and do and
cause to be done such further acts as may be necessary, advisable or proper, at
the reasonable request of the Purchasers, to carry out more effectually the
provisions and purposes of this Agreement. The parties shall use their best
efforts to timely satisfy each of the conditions described in Article VI of this
Agreement.

         5.5 Use of Proceeds. The Seller covenants and agrees that the proceeds
of the Purchase Price shall be used by the Seller for working capital and
general corporate purposes; under no circumstances shall any portion of the
proceeds be applied to:

                  (i) accelerated repayment of debt existing on the date hereof;

                  (ii) the payment of dividends or other distributions on any
         capital stock of the Seller;

                  (iii) increased executive compensation or loans to officers,
         employees, stockholders or directors, unless approved by a
         disinterested majority of the Board of Directors;

                  (iv) the purchase of debt or equity securities of any person,
         including the Seller and its Subsidiaries, except in connection with
         investment of excess cash in high quality (A1/P1 or better) money
         market instruments having maturities of one year or less; or

                  (v) any expenditure not directly related to the business of
         the Seller.

         5.6 Corporate Existence. So long as a Purchaser owns Shares, Warrants
or Warrant Shares, the Seller shall preserve and maintain and cause its
Subsidiaries to preserve and maintain their corporate existence and good
standing in the jurisdiction of their incorporation and the rights, privileges
and franchises of the Seller and its Subsidiaries (except, in each case, in the
event of a merger or consolidation in which the Seller or its Subsidiaries, as
applicable, is not the surviving entity) in each case where failure to so
preserve or maintain could have a Material Adverse Effect on the financial
condition, business or operations of the Seller and its Subsidiaries taken as a
whole.

                                       16
<PAGE>

         5.7 Licenses. The Seller shall, and shall cause its Subsidiaries to,
maintain at all times all material licenses or permits necessary to the conduct
of its business and as required by any governmental agency or instrumentality
thereof, including without limitation all FDA clearances and approvals.

         5.8 Taxes and Claims. The Seller and its Subsidiaries shall duly pay
and discharge (a) all material taxes, assessments and governmental charges upon
or against the Seller or its properties or assets prior to the date on which
penalties attach thereto, unless and to the extent that such taxes are being
diligently contested in good faith and by appropriate proceedings, and
appropriate reserves therefor have been established, and (b) all material lawful
claims, whether for labor, materials, supplies, services or anything else which
might or could, if unpaid, become a lien or charge upon the properties or assets
of the Seller or its Subsidiaries unless and to the extent only that the same
are being diligently contested in good faith and by appropriate proceedings and
appropriate reserves therefor have been established.

         5.9 Perform Covenants. The Seller shall duly comply with all the terms
and covenants contained herein and in each of the instruments and documents
given to the Purchasers in connection with or pursuant to this Agreement, all at
the times and places and in the manner set forth herein or therein.

         5.10     Additional Covenants.

         (a) Except for transactions approved by a majority of the disinterested
directors of the Board of Directors, neither the Seller nor any of its
Subsidiaries shall enter into any transaction with any director, officer,
employee or holder of more than 5% of the outstanding capital stock of any class
or series of capital stock of the Seller or any of its Subsidiaries, member of
the family of any such person, or any corporation, partnership, trust or other
entity in which any such person, or member of the family of any such person, is
a director, officer, trustee, partner or holder of more than 5% of the
outstanding capital stock thereof, with the exception of transactions which are
consummated upon terms that are no less favorable than would be available if
such transaction had been effected at arms-length, in the reasonable judgment of
the Board of Directors.

         (b) The Seller shall timely prepare and file with the Securities and
Exchange Commission the form of notice of the sale of securities pursuant to the
requirements of Regulation D regarding the sale of the Shares and Warrants under
this Agreement.

         (c) The Seller shall timely prepare and file such applications,
consents to service of process (but not including a general consent to service
of process) and similar documents and take such other steps and perform such
further acts as shall be required by the state securities law requirements of
each jurisdiction where a Purchaser resides as indicated on Schedule 1 with
respect to the sale of the Shares and Warrants under this Agreement.

         (d) Neither the Seller nor any of its Affiliates, nor any Person acting
on its or their behalf, shall directly or indirectly make any offers or sales of
any securities or solicit any offers to buy any securities under circumstances
that would cause the loss of the 4(2) exemption under

                                       17
<PAGE>

the Securities Act for the transactions contemplated hereby. Subject to any
consent or approval rights of the Purchasers hereunder, in the event the Seller
contemplates an offering of its equity or debt securities within six months
following the Closing Date, the Seller agrees that it shall notify the
Purchasers of such offering (without providing any material non-public
information to any Purchaser without its prior approval), and upon the
reasonable request of Purchasers purchasing at least 75% of the Shares
hereunder, the Seller shall first disclose the terms and conditions and other
relevant facts of such proposed transaction to Nasdaq and obtain from Nasdaq its
assurance that such transaction will not be integrated with the offering which
is the subject of this Agreement for purposes of the Nasdaq rules requiring
shareholder approval of the issuance of 20% or more of an issuer's outstanding
common stock. In the event the Seller fails to obtain such assurance, then the
Seller shall not issue or sell any such securities without the prior written
consent of Purchasers purchasing at least 75% of the Shares hereunder, provided
that the Seller may sell or issue securities without such consent if (i) it
obtains prior shareholder approval for such sale or issuance in compliance with
NASD rules or (ii) such sale or issuance is to a pharmaceutical company in
connection with a strategic transaction and not primarily as a capital raising
transaction, so long as the Seller has not affirmatively been notified (orally
or in writing) by Nasdaq that it is reasonably likely to treat such sale or
issuance as being integrated with the transactions contemplated under this
Agreement. In the event that the transactions contemplated under this Agreement
are deemed integrated with any other transaction(s) by the NASD, then the Seller
shall as soon as possible seek the approval of its stockholders and take such
other action to authorize the issuance of the full number of Shares and Warrant
Shares and the full amount of securities issued and/or to be issued in such
other transaction.

         5.11 Securities Laws Disclosure; Publicity. The Seller shall (i) on or
promptly after the Closing Date, issue a press release acceptable to SDS Capital
Group SPC, Ltd. disclosing the transactions contemplated hereby, and (ii) after
the Closing Date, file with the Commission a Report on Form 8-K disclosing the
transactions contemplated hereby. Except as provided in the preceding sentence,
neither the Seller nor the Purchasers shall make any press release or other
publicity about the terms of this Agreement or the transactions contemplated
hereby without the prior approval of the other unless otherwise required by law
or the rules of the Commission or Nasdaq.

         5.12 Like Treatment of Purchasers and Holders. Neither the Seller nor
any of its affiliates shall, directly or indirectly, pay or cause to be paid any
consideration (immediate or contingent), whether by way of interest, fee,
payment for redemption, conversion or exercise of the Securities, or otherwise,
to any Purchaser or holder of Securities, for or as an inducement to, or in
connection with the solicitation of, any consent, waiver or amendment to any
terms or provisions of this Agreement or the Related Documents, unless such
consideration is required to be paid to all Purchasers or holders of Securities
bound by such consent, waiver or amendment. The Seller shall not, directly or
indirectly, redeem any Securities unless such offer of redemption is made pro
rata to all Purchasers or holders of Securities, as the case may be, on
identical terms.

         5.13 Independent Nature of Purchasers' Obligations and Rights. The
obligations of each Purchaser under this Agreement or any Related Documents are
several and not joint with the obligations of any other Purchaser, and no
Purchaser shall be responsible in any way for the performance of the obligations
of any other Purchaser under any such agreement. Nothing

                                       18
<PAGE>

contained herein or in any Related Documents, and no action taken by any
Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a
partnership, an association, a joint venture or any other kind of entity, or
create a presumption that the Purchasers are in any way acting in concert or as
a group with respect to such obligations or the transactions contemplated by
such agreement. Each Purchaser shall be entitled to independently protect and
enforce its rights, including without limitation, the rights arising out of this
Agreement or out of the other Related Documents, and it shall not be necessary
for any other Purchaser to be joined as an additional party in any proceeding
for such purpose. Each Purchaser represents that it has been represented by its
own separate legal counsel in its review and negotiation of this Agreement and
the Related Documents. For reasons of administrative convenience only, the
Purchasers acknowledge and agree that they and their respective counsel have
chosen to communicate with the Seller through Wiggin and Dana LLP, but Wiggin
and Dana LLP does not represent any of the Purchasers in this transaction other
than SDS Capital Group SPC, Ltd. (the "Lead Investor").

                       ARTICLE VI - CONDITIONS TO CLOSING

         6.1 Conditions to Obligations of Purchasers to Effect the Closing. The
obligations of a Purchaser to effect the Closing and the transactions
contemplated by this Agreement shall be subject to the satisfaction at or prior
to the Closing, of each of the following conditions, any of which may be waived,
in writing, by a Purchaser:

         (a) The Seller shall deliver or cause to be delivered to each of the
Purchasers the following:

                  1. (i) (A) One or more certificates evidencing the aggregate
         number of Shares of the Common Stock, duly authorized, issued, fully
         paid and non-assessable, as is indicated on Schedule 1 to be purchased
         at the Closing by such Purchaser, registered in the name of such
         Purchaser, in such denominations as is indicated on Schedule 1 for such
         Purchaser ("Share Certificates") or (B) a copy of irrevocable transfer
         agent instructions (I) that have been delivered to the Seller's
         transfer agent and (II) instruct the Seller's transfer agent to issue
         the Share Certificates, (III) that are acknowledged in writing by the
         Company's transfer agent and (IV) that are in form and substance
         satisfactory to the Lead Investor; provided that, in any case, the
         Company shall deliver or cause to be delivered the original Share
         Certificates as soon as practicable following the Closing;

                           (ii) One or more certificates evidencing the
         Warrants, registered in the name of such Purchaser, in such
         denominations as is indicated on Schedule 1 for such Purchaser,
         pursuant to which such Purchaser shall be initially entitled to
         purchase that number of shares of Common Stock as is indicated on
         Schedule 1 or a facsimile copy of such Warrant Certificates, provided
         that, in any case, the Company shall deliver or cause to be delivered
         the original Warrant Certificates as soon as practicable following the
         Closing.

                  2. The Investor Rights Agreement, in the form attached hereto
         as Exhibit B

                                       19
<PAGE>

         (the "Investor Rights Agreement"), duly executed by the Seller.

                  3. A legal opinion of Katten Muchin Zavis Rosenman ("Seller's
         Counsel"), counsel to the Seller, in the form attached hereto as
         Exhibit C.

                  4. A legal opinion of Schreck Brignone ("Nevada Counsel"),
         Nevada counsel to the Seller, in the form attached
         hereto as Exhibit D.

                  5. A certificate of the Secretary of the Seller (the
         "Secretary's Certificate"), in form and substance satisfactory to the
         Purchasers, certifying as follows:

                        (i) that attached to the Secretary's Certificate is a
                  true and complete copy of the Articles of Incorporation of the
                  Seller, as amended, including any and all certificates of
                  designation;

                        (ii) that a true copy of the Bylaws of the Seller, as
                  amended to the Closing Date, is attached to the Secretary's
                  Certificate;

                        (iii) that attached thereto are true and complete copies
                  of the resolutions of the Board of Directors of the Seller
                  authorizing the execution, delivery and performance of this
                  Agreement and the Related Documents, instruments and
                  certificates required to be executed by it in connection
                  herewith and approving the consummation of the transactions in
                  the manner contemplated hereby including, but not limited to,
                  the authorization and issuance of the Shares and Warrants;

                        (iv) the names and true signatures of the officers of
                  the Seller signing this Agreement and all other documents to
                  be delivered in connection with this Agreement;

                        (v) such other matters as required by this Agreement;
                  and

                        (vi) such other matters as the Purchasers may reasonably
                  request.

                  6. A wire transfer representing the amounts due for reasonable
         legal fees and other expenses as described in Section 8.2 hereof.

                  7. Seller shall have applied to each U.S. securities exchange,
         interdealer quotation system and other trading market where its Common
         Stock is currently listed or qualified for trading or quotation for the
         listing or qualification of the Shares and the Warrant Shares for
         trading or quotation thereon in the time and manner required thereby.

                  8. Such other documents as the Purchasers shall reasonably
         request.

                  (b) The Seller shall have entered into a Closing Escrow
Agreement with Wiggin and Dana LLP (the "Escrow Agent") in the form attached
hereto as Exhibit E (the "Closing Escrow Agreement") pursuant to which the
Escrow Agent shall hold certain funds and documents described therein.

                                       20
<PAGE>

         6.2 Conditions to Obligations of the Seller to Effect the Closing. The
obligations of the Seller to effect the Closing and the transactions
contemplated by this Agreement shall be subject to the satisfaction at or prior
to the Closing of each of the following conditions, any of which may be waived,
in writing, by the Seller:

         (a) Each of the Purchasers shall deliver or cause to be delivered to
the Seller (i) payment of the portion of the Purchase Price set forth opposite
each Purchaser's name on Schedule 1, in cash by wire transfer of immediately
available funds to an account designated in writing by Seller prior to the date
hereof; (ii) an executed copy of this Agreement; (iii) an executed copy of the
Investor Rights Agreement; and (iv) such other documents as the Seller shall
reasonably request.

             ARTICLE VII - INDEMNIFICATION, TERMINATION AND DAMAGES

         7.1 Survival of Representations. Except as otherwise provided herein,
the representations and warranties of the Seller and the Purchasers contained in
or made pursuant to this Agreement shall survive the execution and delivery of
this Agreement and the Closing Date and shall continue in full force and effect
for a period of three (3) years from the Closing Date; provided, however, that
the Seller's warranties and representations under Sections 3.13 (Taxes), 3.19
(Subsidiaries and Investments), 3.20 (Capitalization), and 3.21 (Options,
Warrants, Rights), shall survive the Closing Date and continue in full force and
effect until the expiration of all applicable statutes of limitation; and
further provided that the Seller's warranties and representations under Section
3.25 (Environmental Matters) shall survive the Closing Date and continue in full
force and effect for a period of six (6) years from the Closing Date. The
Seller's and the Purchasers' warranties and representations shall in no way be
affected by any investigation of the subject matter thereof made by or on behalf
of the Seller or the Purchasers.

         7.2      Indemnification.

         (a) The Seller agrees to indemnify and hold harmless the Purchasers,
their Affiliates, each of their officers, directors, employees and agents and
their respective successors and assigns, from and against any losses, damages,
or expenses which are caused by or arise out of (i) any breach or default in the
performance by the Seller of any covenant or agreement made by the Seller in
this Agreement or in any of the Related Documents; (ii) any breach of warranty
or representation made by the Seller in this Agreement or in any of the Related
Documents (iii) any and all third party actions, suits, proceedings, claims,
demands, judgments, costs and expenses (including reasonable legal fees and
expenses) incident to any of the foregoing.

         (b) The Purchasers, severally and not jointly, agree to indemnify and
hold harmless the Seller, its Affiliates, each of their officers, directors,
employees and agents and their respective successors and assigns, from and
against any losses, damages, or expenses which are caused by or arise out of (A)
any breach or default in the performance by the Purchasers of any covenant or
agreement made by the Purchasers in this Agreement or in any of the Related
Documents; (B) any breach of warranty or representation made by the Purchasers
in this Agreement or in any of the Related Documents; and (C) any and all third
party actions, suits, proceedings, claims, demands, judgments, costs and
expenses (including reasonable legal fees

                                       21
<PAGE>

and expenses) incident to any of the foregoing; provided, however, that a
Purchaser's liability under this Section 7.2(b) shall not exceed the Purchase
Price paid by such Purchaser hereunder.

         7.3 Indemnity Procedure. A party or parties hereto agreeing to be
responsible for or to indemnify against any matter pursuant to this Agreement is
referred to herein as the "Indemnifying Party" and the other party or parties
claiming indemnity is referred to as the "Indemnified Party". An Indemnified
Party under this Agreement shall, with respect to claims asserted against such
party by any third party, give written notice to the Indemnifying Party of any
liability which might give rise to a claim for indemnity under this Agreement
within sixty (60) business days of the receipt of any written claim from any
such third party, but not later than twenty (20) days prior to the date any
answer or responsive pleading is due, and with respect to other matters for
which the Indemnified Party may seek indemnification, give prompt written notice
to the Indemnifying Party of any liability which might give rise to a claim for
indemnity; provided, however, that any failure to give such notice will not
waive any rights of the Indemnified Party except to the extent the rights of the
Indemnifying Party are materially prejudiced.

         The Indemnifying Party shall have the right, at its election, to take
over the defense or settlement of such claim by giving written notice to the
Indemnified Party at least fifteen (15) days prior to the time when an answer or
other responsive pleading or notice with respect thereto is required. If the
Indemnifying Party makes such election, it may conduct the defense of such claim
through counsel of its choosing (subject to the Indemnified Party's approval of
such counsel, which approval shall not be unreasonably withheld), shall be
solely responsible for the expenses of such defense and shall be bound by the
results of its defense or settlement of the claim. The Indemnifying Party shall
not settle any such claim without prior notice to and consultation with the
Indemnified Party, and no such settlement involving any equitable relief or
which might have an adverse effect on the Indemnified Party may be agreed to
without the written consent of the Indemnified Party (which consent shall not be
unreasonably withheld). So long as the Indemnifying Party is diligently
contesting any such claim in good faith, the Indemnified Party may pay or settle
such claim only at its own expense and the Indemnifying Party will not be
responsible for the fees of separate legal counsel to the Indemnified Party,
unless the named parties to any proceeding include both parties or
representation of both parties by the same counsel would be inappropriate due to
conflicts of interest or otherwise. If the Indemnifying Party does not make such
election, or having made such election does not, in the reasonable opinion of
the Indemnified Party proceed diligently to defend such claim, then the
Indemnified Party may (after written notice to the Indemnifying Party), at the
expense of the Indemnifying Party, elect to take over the defense of and proceed
to handle such claim in its discretion and the Indemnifying Party shall be bound
by any defense or settlement that the Indemnified Party may make in good faith
with respect to such claim. In connection therewith, the Indemnifying Party will
fully cooperate with the Indemnified Party should the Indemnified Party elect to
take over the defense of any such claim. The parties agree to cooperate in
defending such third party claims and the Indemnified Party shall provide such
cooperation and such access to its books, records and properties as the
Indemnifying Party shall reasonably request with respect to any matter for which
indemnification is sought hereunder; and the parties hereto agree to cooperate
with each other in order to ensure the proper and adequate defense thereof.

                                       22
<PAGE>

         With regard to claims of third parties for which indemnification is
payable hereunder, such indemnification shall be paid by the Indemnifying Party
upon the earlier to occur of: (i) the entry of a judgment against the
Indemnified Party and the expiration of any applicable appeal period, or if
earlier, five (5) days prior to the date that the judgment creditor has the
right to execute the judgment; (ii) the entry of an unappealable judgment or
final appellate decision against the Indemnified Party; or (iii) a settlement of
the claim. Notwithstanding the foregoing, the reasonable expenses of counsel to
the Indemnified Party shall be reimbursed on a current basis by the Indemnifying
Party. With regard to other claims for which indemnification is payable
hereunder, such indemnification shall be paid promptly by the Indemnifying Party
upon demand by the Indemnified Party.

                          ARTICLE VIII - MISCELLANEOUS

         8.1 Further Assurances. Each party agrees to cooperate fully with the
other parties and to execute such further instruments, documents and agreements
and to give such further written assurances as may be reasonably requested by
any other party to better evidence and reflect the transactions described herein
and contemplated hereby and to carry into effect the intents and purposes of
this Agreement, and further agrees to take promptly, or cause to be taken, all
actions, and to do promptly, or cause to be done, all things necessary, proper
or advisable under applicable law to consummate and make effective the
transactions contemplated hereby, to obtain all necessary waivers, consents and
approvals, to effect all necessary registrations and filings, and to remove any
injunctions or other impediments or delays, legal or otherwise, in order to
consummate and make effective the transactions contemplated by this Agreement
for the purpose of securing to the parties hereto the benefits contemplated by
this Agreement.

         8.2 Fees and Expenses. The Seller shall be responsible for the payment
of the Purchasers' reasonable legal fees and other third-party expenses relating
to the preparation, negotiation and execution of this Agreement and the Related
Documents and the consummation of the transactions contemplated herein and
therein; which fees and expenses, (excluding any fees and expenses payable
pursuant to the Investor Rights Agreement), shall not exceed $60,000 without the
prior approval of the Seller.

         8.3 Notices. Any and all notices or other communications or deliveries
required or permitted to be provided hereunder shall be in writing and shall be
deemed given and effective on the earliest of (a) the date of transmission, if
such notice or communication is delivered via facsimile at the facsimile number
specified in this Section prior to 5:00 p.m. (New York City time) on a business
day, (b) the next business day after the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number specified in
this Section on a day that is not a business day or later than 5:00 p.m. (New
York City time) on any business day, or (c) the business day following the date
of mailing, if sent by U.S. nationally recognized overnight courier service such
as Federal Express. The address for such notices and communications shall be as
follows:

         If to the Purchasers at each Purchaser's address set forth under its
name on Schedule 1 attached hereto, or with respect to the Seller, addressed to:

                                       23
<PAGE>

                               NexMed, Inc.
                               350 Corporate Boulevard
                               Robbinsville, NJ  08691
                               Attention:  Chief Financial Officer
                               Facsimile No.:  609-208-1622

or to such other address or addresses or facsimile number or numbers as any
such party may most recently have designated in writing to the other parties
hereto by such notice. Copies of notices to the Seller shall be sent to Katten
Muchin Zavis Rosenman, 575 Madison Avenue, New York, NY 10022, Attn: Robert
Kohl, Esq., Facsimile No. (212) 940-8776. Copies of notices to any Purchaser
shall be sent to the addresses, if any, listed on Schedule 1 attached hereto.

         Unless otherwise stated above, such communications shall be effective
when they are received by the addressee thereof in conformity with this Section.
Any party may change its address for such communications by giving notice
thereof to the other parties in conformity with this Section.

         8.4 Governing Law. All questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be governed by and
enforced in accordance with the laws of the State of New York without reference
to the conflicts of laws principles thereof.

         8.5 Jurisdiction and Venue. This Agreement shall be subject to the
exclusive jurisdiction of the Federal District Court, Southern District of New
York and if such court does not have proper jurisdiction, the State Courts of
New York County, New York. The parties to this Agreement agree that any breach
of any term or condition of this Agreement shall be deemed to be a breach
occurring in the State of New York by virtue of a failure to perform an act
required to be performed in the State of New York and irrevocably and expressly
agree to submit to the jurisdiction of the Federal District Court, Southern
District of New York and if such court does not have proper jurisdiction, the
State Courts of New York County, New York for the purpose of resolving any
disputes among the parties relating to this Agreement or the transactions
contemplated hereby. The parties irrevocably waive, to the fullest extent
permitted by law, any objection which they may now or hereafter have to the
laying of venue of any suit, action or proceeding arising out of or relating to
this Agreement, or any judgment entered by any court in respect hereof brought
in New York County, New York, and further irrevocably waive any claim that any
suit, action or proceeding brought in Federal District Court, Southern District
of New York and if such court does not have proper jurisdiction, the State
Courts of New York County, New York has been brought in an inconvenient forum.
Each of the parties hereto consents to process being served in any such suit,
action or proceeding, by mailing a copy thereof to such party at the address in
effect for notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing in
this Section 8.5 shall affect or limit any right to serve process in any other
manner permitted by law.

         8.6 Successors and Assigns. This Agreement is personal to each of the
parties and may not be assigned without the written consent of the other
parties; provided, however, that any of the Purchasers shall be permitted to
assign this Agreement to any Person to whom it assigns or

                                       24
<PAGE>

transfers securities issued or issuable pursuant to this Agreement. Any
assignee must be an "accredited investor" as defined in Rule 501(a) promulgated
under the Securities Act.

         8.7 Severability. If any provision of this Agreement, or the
application thereof, shall for any reason or to any extent be invalid or
unenforceable, the remainder of this Agreement and application of such provision
to other persons or circumstances shall continue in full force and effect and in
no way be affected, impaired or invalidated.

         8.8 Entire Agreement. This Agreement and the other agreements and
instruments referenced herein constitute the entire understanding and agreement
of the parties with respect to the subject matter hereof and supersedes all
prior agreements and understandings.

         8.9 Other Remedies. Except as otherwise provided herein, any and all
remedies herein expressly conferred upon a party shall be deemed cumulative with
and not exclusive of any other remedy conferred hereby or by law, or in equity
on such party, and the exercise of any one remedy shall not preclude the
exercise of any other.

         8.10 Amendment and Waivers. Subject to Section 5.12, any term or
provision of this Agreement may be amended, and the observance of any term of
this Agreement may be waived (either generally or in a particular instance and
either retroactively or prospectively) only by a writing signed by the Seller
and the Purchasers purchasing at least 75% of the Shares hereunder, and such
waiver or amendment, as the case may be, shall be binding upon all Purchasers.
The waiver by a party of any breach hereof or default in the performance hereof
shall not be deemed to constitute a waiver of any other default or any
succeeding breach or default. This Agreement may not be amended or supplemented
by any party hereto except pursuant to a written amendment executed by the
Seller and the Purchasers purchasing at least 75% of the Shares hereunder. No
amendment shall be effected to impact a holder of Securities in a
disproportionately adverse fashion without the consent of such individual
holder.

         8.11 No Waiver. The failure of any party to enforce any of the
provisions hereof shall not be construed to be a waiver of the right of such
party thereafter to enforce such provisions.

         8.12 Construction of Agreement; Knowledge. For purposes of this
Agreement, the term "knowledge," when used in reference to a corporation means
the knowledge of the directors and executive officers of such corporation
(including, if applicable, any person designated as a chief scientific, medical
or technical officer) assuming such persons shall have made inquiry that is
customary and appropriate under the circumstances to which reference is made,
and when used in reference to an individual means the knowledge of such
individual assuming the individual shall have made inquiry that is customary and
appropriate under the circumstances to which reference is made.

         8.13 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original as against any party whose
signature appears thereon and all of which together shall constitute one and the
same instrument. This Agreement shall become binding when one or more
counterparts hereof, individually or taken together, shall bear the signatures
of all of the parties reflected hereon as signatories. In the event that any
signature is

                                       25
<PAGE>

delivered by facsimile transmission, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such facsimile
signature page were an original thereof.

         8.14 No Third Party Beneficiary. Nothing expressed or implied in this
Agreement is intended, or shall be construed, to confer upon or give any person
other than the parties hereto and their respective heirs, personal
representatives, legal representatives, successors and permitted assigns, any
rights or remedies under or by reason of this Agreement.

         8.15 Waiver of Trial by Jury. THE PARTIES HERETO IRREVOCABLY WAIVE
TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR
THE TRANSACTIONS CONTEMPLATED HEREBY.

                            [Signature Page Follows]

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first above written.

SELLER:

NEXMED, INC.


By: /s/ Vivian Liu
Name:  Vivian Liu
Title:  Vice President & CFO

                                       26
<PAGE>

PURCHASER:

Print Exact Name:  Allison Berman Trust



By:  /s/ Barry Praver
     ----------------
Name:  Barry Praver
Title:  Trustee

504 North 4th Street, Suite 102
Fairfield, IA 52556
T: (641) 472-4887
F: (641) 472-6929
Email: ees@lisco.com
SSN/EIN: [omitted]


Amount of Investment:$25,000








                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  Ann Berman Credit Shelter Trust



By:  /s/ Warren Berman
     -----------------
Name:  Warren Berman
Title:  Trustee

504 North 4th Street, Suite 102
Fairfield, IA 52556
T: (641) 472-4887
F: (641) 472-6929
Email: ees@lisco.com
SSN/EIN: [omitted]


Amount of Investment:$50,000








                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  Ari Berman Trust



By:  /s/ Barry Praver
     ----------------
Name:  Barry Praver
Title:  Trustee

504 North 4th Street, Suite 102
Fairfield, IA 52556
T: (641) 472-4887
F: (641) 472-6929
Email: ees@lisco.com
SSN/EIN: [omitted]


Amount of Investment:$25,000








                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  BayStar Capital II, L.P.



By:  /s/ Steve Derby
     ---------------
Name:  Steve Derby
Title:  General Partner of Managing Member Bay East, L.P.

BayStar Capital II, L.P.
c/o BayStar Capital Management, LLC
80 East Sir Francis Drake Blvd
Suite 2B
Larkspur, CA 94939
Tel:     203-967-5875
Fax:     203-967-5851
Email: steve@sdscapital.com
SSN/EIN: [omitted]


Amount of Investment:$1,500,000








                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  Caduceus Capital II, L.P.



By:  /s/ Samuel D. Isaly
     -------------------
Name:  Samuel D. Isaly
Title:

OrbiMed Advisors LLC
767 Third Avenue, 30th floor
New York, NY 10280
T: (212) 739-6400
F: (212) 739-6444
Email: kanareka@orbimed.com
SSN/EIN: [omitted]


Amount of Investment:$1,020,000








                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  Chula Partners, L.P.



By:  /s/ Warren Berman
     -----------------
Name:  Warren Berman
Title:  General Partner

504 North 4th Street, Suite 102
Fairfield, IA 52556
T: (641) 472-4887
F: (641) 472-6929
Email: ees@lisco.com
SSN/EIN: [omitted]


Amount of Investment:$400,000








                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  Clarion Capital Corporation



By:  /s/ Morton A. Cohen
     -------------------
Name:  Morton A. Cohen
Title:  Chairman

1801 East 9th Street
Suite 1120
Cleveland, OH 44114
T: (216) 687-1096
F: (216) 694-3545
Email: tom@clariongrp.com
SSN/EIN: [omitted]


Amount of Investment:$150,000








                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>


PURCHASER:

Print Exact Name:  Clarion Offshore Fund, Ltd.



By:  /s/ Morton A. Cohen
     -------------------
Name:  Morton A. Cohen
Title:  Investment Manager

1801 East 9th Street
Suite 1120
Cleveland, OH 44114
T: (216) 687-1096
F: (216) 694-3545
Email: tom@clariongrp.com
SSN/EIN: [omitted]


Amount of Investment:$50,001








                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>


PURCHASER:

Print Exact Name:  Clarion Partners, L.P.



By:  /s/ Morton A. Cohen
     -------------------
Name:  Morton A. Cohen
Title:  Investment Manager

1801 East 9th Street
Suite 1120
Cleveland, OH 44114
T: (216) 687-1096
F: (216) 694-3545
Email: tom@clariongrp.com
SSN/EIN: [omitted]


Amount of Investment:$50,001








                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  HFR SHC Aggressive Fund



By:  /s/ Samuel D. Isaly
     -------------------
Name:  Samuel D. Isaly
Title:  Managing Member of the Investment Advisor

OrbiMed Advisors LLC
767 Third Avenue, 30th floor
New York, NY 10280
T: (212) 739-6400
F: (212) 739-6444
Email: kanareka@orbimed.com
SSN/EIN: [omitted]


Amount of Investment:$300,000









                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>


PURCHASER:

Print Exact Name:  Midsummer Investment, Ltd.



By:  /s/ Scott D. Kaufman
     --------------------
Name:  Scott D. Kaufman
Title:  Managing Director Midsummer Capital, LLC Acting as Investment Manager of
Midsummer Investment, Ltd.

485 Madison Avenue, 23rd floor
New York, NY 10022
T: (212) 584-2143
F: (212) 584-2142
Email: sk@midsummercapital.com
SSN/EIN: [omitted]


Amount of Investment:$500,000









                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  Penfield Partners, L.P.



By:  /s/ Jeffrey O. Putterman
     ------------------------
Name:  Jeffrey O. Putterman
Title: Limited Partner, Pine Creek Advisors, L.P. (General Partner of Penfield
Partners, L.P.)

c/o William D. Witter, Inc.
153 East 53rd St., 51st Floor
NY, NY 10022-4611
T: (212) 753-7878
F: (212) 486-7697
Email: jputterman@wdwitter.com
SSN/EIN: [omitted]


Amount of Investment:$600,000









                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  SDS Capital Group SPC, Ltd.



By:  /s/ Steve Derby
     ---------------
Name:  Steve Derby
Title: Managing Member

c/o SDS Management, LLC
53 Forest Avenue, 2nd floor
Old Greenwich, CT 06870
Tel:     203-967-5850
Fax:     203-967-5851
Email: steve@sdscapital.com
SSN/EIN: [omitted]



Amount of Investment:$750,000









                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  Summit Capital Partners, LP



By:  /s/ Matthew C. Rudolf
     ---------------------
Name:  Matthew C. Rudolf
Title:  Managing Director Summit Capital Management, LLC, General Partner
Summit Capital Partners, L.P.

601 Union Street, Suite 3900
Seattle, WA 98101-4054
Tel: 206-447-6200
Fax: 206-447-6204
Email: matt@summitcapital.com
SSN/EIN: [omitted]



Amount of Investment:$300,000









                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]


<PAGE>

PURCHASER:

Print Exact Name:  The Tail Wind Fund Ltd.



By:  Tail Wind Advisory and Management Ltd., as investment manager

By:  /s/ David Crook
     ---------------
Name:  David Crook
Title:  CEO

Addresses for Notices:

<TABLE>
<CAPTION>

     <S>                                               <C>
--------------------------------------------------- -------------------------------------------------------
The Tail Wind Fund Ltd.                             With a copy to:
                                                    ---------------
c/o Tail Wind Advisory & Management Ltd.
1st Floor, No. 1 Regent Street                      Peter J. Weisman, P.C.
London, SW1Y 4NS UK                                 335 Madison Avenue, Ste 1702
T: (44) 20-7468-7660                                New York, NY 10017
F:  (44) 20-7468-7657                               T: (212) 418-4972
Contact: David Crook                                F: (212) 317-8855
Email: dcrook@tailwindam.com                        Email:  pweisman@pweisman.com
--------------------------------------------------- -------------------------------------------------------

--------------------------------------------------- -------------------------------------------------------
Common Stock Delivered to:                          Warrants Delivered to:

c/o Bishop Rosen & Co.                              The Tail Wind Fund Ltd.
100 Broadway, 16th Floor                            c/o The Bank of Nova Scotia Trust Company (Bahamas)
New York, NY 10005                                  Limited
Attn: Dan Freedman                                  Windermere House, 404 East Bay Street
Telephone: (212) 602-0654                           Nassau, Bahamas
Facsimile: (212) 602-0697                           Attention: Ngaire Strachan
                                                    Telephone :  (242) 393-8777
                                                    Facsimile:  (242) 393-0582
--------------------------------------------------- -------------------------------------------------------
</TABLE>

SSN/EIN: [omitted]



Amount of Investment:$500,000



[Omnibus NexMed, Inc. Common Stock and Warrant Purchase Agreement Signature
Page]

<PAGE>

PURCHASER:

Print Exact Name: Winchester Global Trust Company Limited as Trustee for
Caduceus Capital Trust



By:  /s/ Samuel D. Isaly
     -------------------
Name:  Samuel D. Isaly
Title:  Managing Member of the Investment Advisor

OrbiMed Advisors LLC
767 Third Avenue, 30th floor
New York, NY 10280
T: (212) 739-6400
F: (212) 739-6444
Email: kanareka@orbimed.com
SSN/EIN: [omitted]


Amount of Investment:$2,055,000









                     [Omnibus NexMed, Inc. Common Stock and
                   Warrant Purchase Agreement Signature Page]

<PAGE>

            SCHEDULE 1 TO COMMON STOCK AND WARRANT PURCHASE AGREEMENT

               PURCHASERS AND SHARES OF COMMON STOCK AND WARRANTS

<TABLE>
<CAPTION>
     <S>                                        <C>                     <C>                    <C>                     <C>
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
NAME, ADDRESS AND FAX NUMBER                COPIES OF NOTICES TO    SHARES OF COMMON STOCK COMMON STOCK UNDERLYING  PURCHASE PRICE
       OF PURCHASER                                                    STOCK PURCHASED       UNDERLYING WARRANTS
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Allison Berman Trust
504 North 4th Street, Suite 102
Fairfield, IA 52556                                                         16,667                    5,833              $25,000
T: (641) 472-4887
F: (641) 472-6929
Email: ees@lisco.com
Contact: Barry Praver
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Ann Berman Credit Shelter Trust
504 North Fourth Street, Suite 102
Fairfield, IA 52556                                                         33,333                   11,667              $50,000
T: (641) 472-4887
F: (641) 472-6929
Contact: Warren Berman
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Ari Berman Trust
504 North Fourth Street, Suite 102
Fairfield, IA 52556                                                         16,667                    5,833              $25,000
T: (641) 472-4887
F: (641) 472-6929
Contact: Warren Berman
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------

<PAGE>

------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
NAME, ADDRESS AND FAX NUMBER                COPIES OF NOTICES TO    SHARES OF COMMON STOCK COMMON STOCK UNDERLYING  PURCHASE PRICE
       OF PURCHASER                                                    STOCK PURCHASED       UNDERLYING WARRANTS
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
BayStar Capital II, L.P.
c/o BayStar Capital Management, LLC
80 East Sir Francis Drake Blvd
Suite 2B                                                                  1,000,000                  350,000           $1,500,000
Larkspur, CA 94939
Tel:     203-967-5875
Fax:     203-967-5851
Contact: Steve Derby
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Chula Partners, L.P.
504 North Fourth Street, Suite 102
Fairfield, IA 52556                                                        266,667                   93,333             $400,000
T: (641) 472-4887
F: (641) 472-6929
Contact: Warren Berman
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Clarion Capital Corporation
1801 East 9th Street
Suite 510                                                                  100,000                   35,000             $150,000
Cleveland, OH 44114
T: (216) 687-8948
F: (216) 694-3545
Contact: Morton Cohen
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------

<PAGE>

------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
NAME, ADDRESS AND FAX NUMBER                COPIES OF NOTICES TO    SHARES OF COMMON STOCK COMMON STOCK UNDERLYING  PURCHASE PRICE
       OF PURCHASER                                                    STOCK PURCHASED       UNDERLYING WARRANTS
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Clarion Offshore Fund, Ltd.
1801 East 9th Street
Suite 510                                                                   33,334                   11,667              $50,001
Cleveland, OH 44114
T: (216) 687-8948
F: (216) 694-3545
Contact: Morton Cohen
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Clarion Partners, L.P.
1801 East 9th Street
Suite 510                                                                   33,334                   11,667              $50,001
Cleveland, OH 44114
T: (216) 687-8948
F: (216) 694-3545
Contact: Morton Cohen
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------

<PAGE>

------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
NAME, ADDRESS AND FAX NUMBER                COPIES OF NOTICES TO    SHARES OF COMMON STOCK COMMON STOCK UNDERLYING  PURCHASE PRICE
       OF PURCHASER                                                    STOCK PURCHASED       UNDERLYING WARRANTS
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Midsummer Investment, Ltd.
485 Madison Avenue, 23rd floor
New York, NY 10022                                                         333,333                   116,667            $500,000
T: (212) 584-2140
F: (212) 584-2142
Contact: Michel A. Amsalem
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Winchester Global Trust Company Limited
as Trustee for Caduceus Capital Trust

c/o OrbiMed Advisors LLC                                                  1,370,000                  479,500           $2,055,000
767 Third Avenue, 30th floor
New York, NY 10280
T: (212) 739-6410
F: (212) 739-6444
Contact: Sven Borho
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Caduceus Capital II, L.P.

c/o OrbiMed Advisors LLC
767 Third Avenue, 30th floor                                               680,000                   238,000           $1,020,000
New York, NY 10280
T: (212) 739-6410
F: (212) 739-6444
Contact: Sven Borho
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------

<PAGE>

------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
NAME, ADDRESS AND FAX NUMBER                COPIES OF NOTICES TO    SHARES OF COMMON STOCK COMMON STOCK UNDERLYING  PURCHASE PRICE
       OF PURCHASER                                                    STOCK PURCHASED       UNDERLYING WARRANTS
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
HFR SHC Aggressive Fund

c/o OrbiMed Advisors LLC
767 Third Avenue, 30th floor                                               200,000                   70,000             $300,000
New York, NY 10280
T: (212) 739-6410
F: (212) 739-6444
Contact: Sven Borho
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Penfield Partners, L.P.
c/o William D. Witter, Inc.
153 East 53rd St., 51st Floor                                              400,000                   140,000            $600,000
NY, NY 10022-4611
T: (212) 753-7878
F: (212) 486-7697
Contact: Jeff Putterman
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
SDS Capital Group SPC, Ltd.                Mike Grundei
c/o SDS Management, LLC                    Wiggin & Dana LLP
53 Forest Avenue, 2nd Floor                400 Atlantic Street             500,000                   175,000            $750,000
Old Greenwich, CT 06870                    Stamford, CT 06901
T: (203) 967-5875                          T: (203) 363-7630
F: (203) 967-5851                          F: (203) 363-7676
Contact: Steve Derby
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------

<PAGE>

------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
NAME, ADDRESS AND FAX NUMBER                COPIES OF NOTICES TO    SHARES OF COMMON STOCK COMMON STOCK UNDERLYING  PURCHASE PRICE
       OF PURCHASER                                                    STOCK PURCHASED       UNDERLYING WARRANTS
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Summit Capital Partners, LP
601 Union Street, Suite 3900
Seattle, WA 98101-4054                                                     200,000                   70,000             $300,000
Tel: 206-447-6200
Fax: 206-447-6204
Contact: Jack Morbeck
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
The Tail Wind Fund Ltd.

Address for Notices:

c/o Tail Wind Advisory & Management Ltd.
1st Floor, No. 1 Regent Street
London, SW1Y 4NS UK                   Peter J. Weisman, P.C.
T: (44) 20-7468-7660                  335 Madison Avenue, Ste 1702
F:  (44) 20-7468-7657                 New York, NY 10017                   333,333                   116,667            $500,000
Contact: David Crook                  T: (212) 418-4972
                                      F: (212) 317-8855
Common Stock Delivered:

c/o Bishop Rosen & Co.
100 Broadway, 16th Floor
New York, NY 10005
T: (212) 602-0654
F: (212) 602-0697
Contact: Dan Freeman
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------

<PAGE>


------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
NAME, ADDRESS AND FAX NUMBER                COPIES OF NOTICES TO    SHARES OF COMMON STOCK COMMON STOCK UNDERLYING  PURCHASE PRICE
       OF PURCHASER                                                    STOCK PURCHASED       UNDERLYING WARRANTS
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------






















------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------



<PAGE>

------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
NAME, ADDRESS AND FAX NUMBER                COPIES OF NOTICES TO    SHARES OF COMMON STOCK COMMON STOCK UNDERLYING  PURCHASE PRICE
       OF PURCHASER                                                    STOCK PURCHASED       UNDERLYING WARRANTS
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
Warrants Delivered to:

c/o The Bank of Nova Scotia Trust
 Company (Bahamas) Limited
Windermere House, 404 East Bay Street
Nassau, Bahamas
T: 242) 393-8777
F: (242) 393-0582
Contact: Ngaire Strachan

------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
TOTALS:                                                                   5,516,668                 1,615,834          $8,275,002
------------------------------------------ ------------------------ ---------------------- ----------------------- ----------------
</TABLE>